TAM Receptor Modulators for Immune Response Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and treatments for diseases like sepsis and autoimmune disorders are either ineffective or come with significant side effects, and there is a need for improved immunoadjuvants and immunomodulatory agents that can enhance or suppress immune responses effectively.
Innovation Solution
The use of TAM receptor inhibitors for immunoenhancement and TAM receptor agonists for immunosuppression, where TAM receptor inhibitors enhance immune responses by reducing receptor activity and TAM receptor agonists suppress immune responses by increasing receptor activity, administered as vaccine adjuvants, treatments for sepsis, and therapies for autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines and treatments are used, then they provide basic immune protection, but they lack effectiveness or cause significant side effects
Solution Approach 1:
The patent changes the functional state of TAM receptors from inactive to active (using agonists) or from active to inactive (using antagonists) to achieve desired immune responses. This parameter change in receptor activity enables effective immune modulation without the harmful side effects of conventional treatments like glucocorticoids and calcineurin inhibitors.
Solution Approach 2:
The patent introduces TAM receptor agonists and antagonists as intermediary substances that mediate immune responses. These intermediaries specifically target TAM receptors to enhance or suppress immune activity, providing a more precise and safer alternative to non-specific immunosuppressants and immunostimulants.
2Reliability
If TAM receptor activity is increased, then immune suppression is achieved for autoimmune diseases, but the mechanism becomes more complex
Solution Approach 1:
The patent segments the immune suppression function by specifically targeting only the TAM receptor pathway rather than suppressing the entire immune system. This selective approach simplifies the overall mechanism while achieving effective immunosuppression for autoimmune diseases through targeted agonist activation.
3Reliability
If TAM receptor activity is decreased, then immune enhancement is achieved for vaccines and sepsis, but the mechanism becomes more complex
Solution Approach 1:
The patent segments the immune enhancement function by specifically activating only the TAM receptor pathway rather than providing broad immunostimulation. This targeted approach simplifies the mechanism while achieving effective immune enhancement for vaccines and sepsis treatment through selective antagonist activation.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
This disclosure concerns compositions and methods for immunoenhancement and/or immunosuppression. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor for immunoenhancement, for example as a vaccine adjuvant, for the treatment of sepsis, or for treating an immunocompromised subject. Also disclosed are methods of screening for immunoenhancing agents. In other embodiments, the disclosure concerns methods of using a TAM receptor agonist for immunosuppression, for example as a treatment for an autoimmune disorder, for the treatment of an allergy, or for treating graft-versus-host disease in a subject. Also disclosed are methods of screening for immunosuppressive agents.